Oral Semaglutide Outperforms Dapagliflozin for Liver Health in Diabetic Fatty Liver Disease
In 187 patients with type 2 diabetes and fatty liver disease, oral semaglutide significantly reduced liver stiffness and improved metabolic markers over 6 months compared to dapagliflozin.
Quick Facts
What This Study Found
Oral semaglutide significantly reduced liver stiffness (8.07 ± 2.90 → 6.51 ± 3.09 kPa, p<0.001) measured by VCTE at 6 months. Both groups showed reduced BMI, waist circumference, and waist-to-hip ratio. Semaglutide showed notable HbA1c decrease (p-value referenced). Both were add-on to metformin.
Key Numbers
Comparison focused on patients with both T2DM and MASLD/MASH. MASLD is associated with cirrhosis and hepatocellular carcinoma risk.
How They Did This
Prospective cohort study of 187 patients with T2DM at a single center. 95 patients received oral semaglutide and 92 received dapagliflozin, both added to metformin. Liver assessment by vibration-controlled transient elastography (VCTE) for steatosis and fibrosis at baseline and 6 months. Anthropometric and metabolic parameters measured.
Why This Research Matters
Fatty liver disease affects up to 70% of type 2 diabetes patients and is a growing cause of liver transplantation. Finding that oral semaglutide significantly reduces liver stiffness — a marker of fibrosis progression — provides evidence for choosing GLP-1 agonists over SGLT2 inhibitors when liver health is a clinical priority.
The Bigger Picture
The intersection of diabetes, obesity, and liver disease represents one of the largest unmet needs in medicine. GLP-1 receptor agonists are emerging as uniquely positioned to treat all three conditions simultaneously. Semaglutide is already being studied specifically for liver fibrosis (MASH) treatment, and this real-world data supports its liver benefits.
What This Study Doesn't Tell Us
Non-randomized design with potential selection bias between treatment groups. Single center in Romania may limit generalizability. 6-month follow-up is relatively short for assessing liver outcomes. VCTE is an indirect measure of fibrosis — liver biopsy remains the gold standard. The abstract mentions a significant p-value for HbA1c but doesn't clearly report the value.
Questions This Raises
- ?Does oral semaglutide's liver benefit persist beyond 6 months and translate to reduced liver-related clinical events?
- ?Would combining semaglutide with dapagliflozin provide additive liver benefits?
Trust & Context
- Key Stat:
- 8.07 → 6.51 kPa liver stiffness Oral semaglutide significantly reduced liver stiffness — a marker of fibrosis — over 6 months in patients with diabetes and fatty liver disease (p<0.001)
- Evidence Grade:
- Moderate evidence from a prospective cohort study with appropriate objective outcome measures (VCTE). Strengthened by the comparative design but limited by non-randomization.
- Study Age:
- Published in 2024, contributing real-world evidence as semaglutide is actively being evaluated for MASH treatment in Phase 3 trials.
- Original Title:
- New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.
- Published In:
- Diagnostics (Basel, Switzerland), 14(14) (2024)
- Authors:
- Stratina, Ermina, Stanciu, Carol, Nastasa, Robert, Zenovia, Sebastian, Stafie, Remus, Rotaru, Adrian, Cuciureanu, Tudor, Muzica, Cristina, Sfarti, Catalin, Girleanu, Irina, Minea, Horia, Petrea, Oana, Huiban, Laura, Chiriac, Stefan, Singeap, Ana-Maria, Vlad, Oana, Cojocariu, Camelia, Trifan, Anca
- Database ID:
- RPEP-09328
Evidence Hierarchy
Frequently Asked Questions
What is MASLD and why does it matter for diabetes patients?
MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) means fat buildup in the liver related to metabolic problems. It affects up to 70% of type 2 diabetes patients and can progress to liver scarring (fibrosis), cirrhosis, and liver cancer. Treating the underlying diabetes with drugs that also help the liver is therefore particularly valuable.
What does liver stiffness measurement tell us?
Liver stiffness, measured non-invasively by FibroScan (VCTE), reflects the amount of scar tissue in the liver. Higher stiffness means more fibrosis. The decrease from 8.07 to 6.51 kPa with semaglutide suggests reduced liver scarring, moving many patients from mild fibrosis toward normal range.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09328APA
Stratina, Ermina; Stanciu, Carol; Nastasa, Robert; Zenovia, Sebastian; Stafie, Remus; Rotaru, Adrian; Cuciureanu, Tudor; Muzica, Cristina; Sfarti, Catalin; Girleanu, Irina; Minea, Horia; Petrea, Oana; Huiban, Laura; Chiriac, Stefan; Singeap, Ana-Maria; Vlad, Oana; Cojocariu, Camelia; Trifan, Anca. (2024). New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.. Diagnostics (Basel, Switzerland), 14(14). https://doi.org/10.3390/diagnostics14141475
MLA
Stratina, Ermina, et al. "New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.." Diagnostics (Basel, 2024. https://doi.org/10.3390/diagnostics14141475
RethinkPeptides
RethinkPeptides Research Database. "New Insights on Using Oral Semaglutide versus Dapagliflozin ..." RPEP-09328. Retrieved from https://rethinkpeptides.com/research/stratina-2024-new-insights-on-using
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.